Serological speciation of human schistosome infections by ELISA with a panel of three antigens

P Turner, K Laloo, J Bligh, M Armstrong, C J M Whitty, M J Doenhoff, P L Chiodini

Aims: To find out whether serology can reliably speciate human schistosomiasis using a simple enzyme linked immunosorbent assay (ELISA) technique.

Methods: Stored sera from 66 patients with microscopically confirmed schistosomiasis were subjected to ELISA using a panel of three antigens, namely: unfractionated *Schistosoma mansoni* soluble egg antigen (SEA); CEF6, a cationic fraction of SEA; and crude *S margrebowiei* egg antigen, prepared from an animal schistosome closely related to *S haematobium*.

Results: The optical densities (ODs) obtained using CEF6 as antigen were significantly higher in sera from *S mansoni* infected patients than in sera from *S haematobium* infected patients (median OD, 0.810 v 0.595). Using *S margrebowiei* egg antigen, the optical densities were significantly higher in *S haematobium* sera than in *S mansoni* sera (median OD, 0.794 v 0.544). There was no significant difference in optical densities between *S mansoni* and *S haematobium* sera using SEA (median OD, 0.725 v 0.737). The ratio of ODs (CEF6 to *S margrebowiei* egg antigen) was calculated: a ratio of >1 indicated *S mansoni* infection (sensitivity, 88%) and a ratio of <1 indicated *S haematobium* infection (sensitivity, 84%). The odds ratio for *S haematobium* having an OD ratio of <1 was 36.8 (95% confidence interval, 7.0 to 194).

Conclusions: The identity of the infecting species of schistosome can be determined using the panel of antigens described. SEA should be used to screen serum samples, and the CEF6 : *S margrebowiei* egg antigen ELISA optical density ratio can be used where serological speciation is required.

Schistosomiasis remains an important infection for people living in and travelling to tropical countries. Figures suggest that there are currently 200 million people suffering from schistosomiasis. The laboratory diagnosis of schistosomiasis can be achieved by both microscopic and serological methods. Schistosome ova may be seen in membrane filtered terminal urine, formol/ether concentrated stools, and biopsy specimens. Microscopy has a specificity of 100% in expert hands, but variable sensitivity. Ova were found in only 45% of 1107 patients from Africa diagnosed serologically with schistosomiasis in the UK. There are a variety of serological methods available for the diagnosis of schistosomiasis. The Hospital for Tropical Diseases in London (HTD) uses an enzyme linked immunosorbent assay (ELISA) with crude *S. mansoni* soluble egg antigen (SEA), which has a published specificity of 97% and sensitivities of 96% (*S. mansoni*) and 92% (*S. haematobium*). The SEA ELISA is a good serological screening test for schistosomiasis, but gives no indication of the infecting species of schistosome. The Centers for Disease Control in the USA screen sera by falcon assay screening test (FAST)-ELISA using *S. mansoni* adult worm microsomal antigen and subsequently confirm the results with a species specific immunoblot. They report excellent sensitivity and specificity for both the ELISA and the immunoblot.

A cationic fraction of *S. mansoni* egg homogenate, known as CEF6, contains the antigens ω-1 and ω-1. In several studies, CEF6 has been found to be potentially useful for the serodiagnosis of *S. mansoni* infections. In a large collaborative study, Mott and Dixon reported that ELISA using CEF6 had a sensitivity of 91.7% and a specificity of 90.0% for *S. mansoni* infection. However, Doenhoff and colleagues noted that sera from patients with *S. haematobium* infection significantly crossreacted with CEF6, and were only marginally less reactive against CEF6 than *S. mansoni* sera. This somewhat limits the usefulness of CEF6 for the specific serodiagnosis of *S. mansoni* infections because there are geographical areas where both *S. haematobium* and *S. mansoni* are endemic. Crossreactivity of sera from *S. japonicum* infected patients with CEF6 has been demonstrated, but this is of less clinical relevance because *S. japonicum* is not known to coexist with *S. mansoni*.

"The speciation of schistosomiasis is important because screening for species specific complications, such as bladder carcinoma in Schistosoma haematobium infection, is necessary in those chronically exposed."

*Schistosoma haematobium* antigens are not easily obtained: the life cycle of *S. haematobium* is difficult to maintain in the laboratory and egg yields are low. However, a closely related species of schistosome, *S. margrebowiei*, grows well in laboratory mice. *Schistosoma margrebowiei* commonly infects African antelopes and other herbivores. Antigens derived from the ova of *S. margrebowiei* might be expected to crossreact with antibodies present in the sera of patients infected with *S. haematobium*, providing a more specific test for *S. haematobium* infection.

Previous work at HTD (M El-Tahawy et al, 1992, unpublished data) has suggested that it is possible to speciate schistosome infections serologically by ELISA using a combination of CEF6 and *S. margrebowiei* egg antigens. Our present study set out to confirm that the infecting species of schistosome could be reliably identified from blood using ELISA with a panel of three antigens, namely: SEA, CEF6, and crude *S. margrebowiei* egg antigen.

---

**Abbreviations:** ELISA, enzyme linked immunosorbent assay; FAST, falcon assay screening test; HTD, Hospital for Tropical Diseases London; OD, optical density; SEA, *Schistosoma mansoni* soluble egg antigen.
and *S margrebowiei* egg antigen. The speciation of schistosomiasis is important because, although the treatment for *S haematobium* and *S mansoni* infections is the same, screening for species specific complications, such as bladder carcinoma in *S haematobium* infection, is necessary in those chronically exposed. Obviously, this is only applicable in a minority of those patients presenting with schistosomiasis in the UK. Species specific serological tests will also be useful in epidemiological studies of schistosomiasis.

**METHODS**

Sera from 66 patients, stored after routine diagnostic testing for schistosomal antibodies, were used in our study. The patients were diagnosed with schistosomiasis at HTD between 1989 and 2002. In all patients, the diagnosis had been confirmed by the identification of ova on microscopy of urine, stool, or biopsy material. Appropriate sera were identified by searching the hospital pathology results computer, the parasitology laboratory positive findings book, and a departmental schistosomiasis patient database. All HTD patients with a confirmed microscopic diagnosis of schistosomiasis and an available pretreatment serum sample were included in our study.

All sera were stored at −20°C before analysis.

**Preparation of the test antigens**

The SEA and CEF6 antigens were prepared as described by Dunne et al. Schistosoma *margrebowiei* was obtained from Malawi and maintained in the laboratory by passage in Bulinus *natalensis* snails and laboratory mice. Crude *S margrebowiei* soluble egg antigen was prepared by the same method used by Dunne and colleagues to prepare *S mansoni* SEA.

The protein concentrations of the CEF6 and *S margrebowiei* egg antigen preparations were determined using the method described by Lowry et al. SEA of known concentration was used from the HTD clinical parasitology laboratory antigen stock. The antigen preparations were stored at −20°C.

**Immobilisation of the test antigens on microtitre plates**

Ninety six well, flat bottomed microtitre plates (Immulon® 2HB; Thermo Labsystems, Franklin, Massachusetts, USA) were used for all of the ELISAs. An appropriate amount of each antigen (as determined by chequerboard titration with reference positive and negative sera) was diluted in coating buffer (carbonate/bicarbonate buffer; pH 9.6) and 150 µl aliquots of these dilutions were dispensed into each well of separate microtitre plates using a multichannel pipette. The plates were covered and incubated at 26–30°C for two hours. The optical density (OD) of the positive control sample was monitored at 490 nm using a Ceres 900i ELISA reader (Bio-tek Instruments Inc) until the target value was reached. The optical density (OD) reached its target value (calculated during the chequerboard experiment: 0.800 for SEA, 1.150 for CEF6, and 1.000 for *S margrebowiei* egg antigen). All sera were tested in duplicate and the arithmetic mean of the two OD results was calculated.

**Statistical analysis**

The data were analysed using STATA™ version 7 software (STATAcorp, College Station, Texas, USA). The two sample Wilcoxon rank sum test was used to compare OD results for each antigen. The OD ratios were compared using the χ² test and the odds ratios were calculated by logistic regression.

**RESULTS**

Table 1 shows the results of the ELISAs using the three test antigens. There was no significant difference in ODs between sera from *S haematobium* infected patients and sera from those infected by *S mansoni* using SEA as the ELISA antigen (p = 0.9). However, using CEF6 as the antigen, the optical densities were significantly higher in *S mansoni* sera compared with *S haematobium* sera (p = 0.03). With the *S margrebowiei* egg antigen, *S haematobium* sera gave significantly higher optical densities than *S mansoni* sera (p = 0.0004).

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Results obtained with the three test antigens SEA, CEF6, and <em>Schistosoma margrebowiei</em> egg antigen in sera from patients with confirmed <em>S haematobium</em> or <em>S mansoni</em> infection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>S haematobium</em> (<em>n = 50</em>)</td>
</tr>
<tr>
<td>SEA 0.737 (0.635 to 0.796)</td>
<td>0.725 (0.630 to 0.799)</td>
</tr>
<tr>
<td>CEF6 0.595 (0.476 to 0.698)</td>
<td>0.810 (0.540 to 1.100)</td>
</tr>
<tr>
<td><em>S margrebowiei</em> egg antigen 0.794 (0.675 to 0.936)</td>
<td>0.544 (0.389 to 0.649)</td>
</tr>
<tr>
<td>ODCEF6:OD<em>S margrebowiei</em> egg antigen 0.785 (0.624 to 0.910)</td>
<td>1.307 (1.123 to 1.897)</td>
</tr>
</tbody>
</table>

Optical densities (ODs) were measured at 490 nm. The data are presented as the median value (interquartile range).
A ratio of the ODs for each serum sample was calculated (OD_{CEF6} : OD_{S margrebowiei egg antigen}). The median ratio was < 1 for S haematobium sera and > 1 for S mansoni sera (p < 0.00001) (table 1). The odds ratio for a S haematobium serum having an OD ratio of < 1 was 36.8 (95% confidence interval, 7.0 to 194; p < 0.001). The odds ratio for S mansoni serum having an OD of < 1 was 0.27 (95% confidence interval, 0.01 to 0.14; p < 0.001). Table 2 shows the distribution of sera according to microscopy result and OD ratio. For S haematobium infection, when the OD ratio was < 1, the test had a sensitivity of 84%; for S mansoni infection, when the OD ratio was > 1, the test had a sensitivity of 88%. We calculated that, in this patient group, the OD ratio had a positive predictive value of 95% for S haematobium and 64% for S mansoni. Although the presence of either S haematobium or S mansoni ova in clinical samples proves that they are present, it is impossible to rule out mixed infection where one species is not visible microscopically (because the sensitivity of microscopy is poor). Therefore, we think that specificities and negative predictive values would not be reliable and have not quoted them.

DISCUSSION

Schistosomiasis is a major health issue in the tropics and subtropics. Increasing numbers of cases are being reported in short term visitors to endemic countries. It is important to have accurate and cheap methods of diagnosis.

Microscopic methods of diagnosing schistosomiasis are cheap, but are time consuming and have poor sensitivity, although they have excellent specificity. Therefore, sensitive serological tests have the potential to increase diagnostic yield, especially in those with light infection who excrete few eggs. Unfortunately, current ELISA techniques using S mansoni soluble egg antigen cannot differentiate between S haematobium and S infections. Serological speciation would be useful in patients who have been diagnosed with schistosomiasis on the basis of clinical features and SEA ELISA, but in whom ova cannot be found in clinical material. The Centre for Disease Control in Atlanta provides serological speciation of schistosomiasis using a combination of FAST-ELISA and immunoblotting; this technique is both sensitive and specific but the immunoblotting is difficult and expensive to perform. We feel that this would not be a practical technique in a busy laboratory such as the clinical parasitology laboratory at HTD, where approximately 5000 requests for schistosome ELISA are processed each year.

Our experiments have shown that CEF6 is significantly more specific for S mansoni infections, a result that agrees with previously reported findings. However, there is still some overlap in ODs between S mansoni and S haematobium sera using CEF6 as the ELISA antigen. We have found that if S margrebowiei egg antigen is used, significantly higher ODs are obtained with S haematobium sera. Using both CEF6 and S margrebowiei egg antigens in parallel allows a ratio of ODs to be calculated. We have shown that a ratio of OD_{CEF6} : OD_{S margrebowiei egg antigen} of < 1 is highly likely to represent S haematobium infection, when compared with the gold standard of identification of ova in clinical material.

“We have found that if Schistosoma margrebowiei egg antigen is used, significantly higher optical densities are obtained with S haematobium sera”

Relatively small numbers of sera were tested in our study, with most (around three quarters) being from patients with S haematobium infection. The positive predictive value of the OD ratio will be altered by any change in the relative proportions of S haematobium and S mansoni infection in the test group. However, it is reassuring to note that the proportion of patients diagnosed with microscopically confirmed S haematobium infection was similar (68%) in the large HTD case series reported by Whitty et al.

We are now able to provide reliable serological schistosome speciation in those instances in which it might be useful—for example, in microscopically negative patients thought to be chronically infected and thus more likely to be at risk of complications. We envisage that SEA ELISA will be used as a screening test, followed up with CEF6 and S margrebowiei egg antigen ELISA if microscopy of stool and urine is negative.

ACKNOWLEDGEMENTS

We are grateful to Dr V Southgate, Natural History Museum, London for providing a life cycle of S margrebowiei and to the Wellcome Trust for financial support for the provision of antigenic material.

Take home messages

- We tested an enzyme linked immunosorbent assay (ELISA) on sera of patients with confirmed schistosomiasis using a panel of three antigens: unfractionated Schistosoma mansoni soluble egg antigen (SEA); CEF6, a cationic fraction of SEA; and crude S margrebowiei egg antigen, prepared from an animal schistosome closely related to S haematobium.
- Using this panel of antigens, we were able to identify the infecting species of schistosome
- SEA should be used to screen serum samples, and the CEF6 : S margrebowiei egg antigen ELISA optical density ratio should be used where serological speciation is required
- This will be useful in microscopically negative patients thought to be chronically infected and thus more likely to be at risk of complications

REFERENCES


Table 2 Optical density ratio (OD_{CEF6} : OD_{S margrebowiei egg antigen}) of test sera compared with parasitological diagnosis

<table>
<thead>
<tr>
<th>Microscopic diagnosis</th>
<th>S haematobium</th>
<th>S mansoni</th>
</tr>
</thead>
<tbody>
<tr>
<td>OD ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 1</td>
<td>8</td>
<td>14</td>
</tr>
<tr>
<td>≤ 1</td>
<td>42</td>
<td>2</td>
</tr>
</tbody>
</table>

Authors’ affiliations

P Turner, K Lalloo, J Bligh, M Armstrong, C J M Whitty, P L Chiodini, The Hospital for Tropical Diseases, Capper Street, London WC1E 6AU, UK
M J Doenhoff, School of Biological Sciences, University of Wales, Deiniol Road, Bangor, Gwynedd LL57 2UW, Wales, UK

www.jclinpath.com

**ECHO**

**Childhood onset SLE found to be associated with oestrogen receptor α gene polymorphism**

For the first time, children developing systemic lupus erythematosus (SLE) under the age of 16 have been found to have significantly different polymorphisms of the PvuII and Xbal genes for oestrogen receptor α (ORα) compared to those developing the disease over the age of 16.

In a case-control study carried out in Korea of 137 female patients with SLE and 268 matched controls, 41 cases developed the disease under the age of 16. Genomic DNA was extracted from the peripheral blood of all participants, and PvuII and Xbal restriction fragment length polymorphisms of ORα investigated using polymerase chain reaction primers.

PP, Pp and xx genotypes occurred significantly less frequently in cases developing SLE in childhood than in controls (p = 0.005, 0.05, and 0.026 respectively). The PP genotype also occurred significantly less frequently in childhood onset than adult onset SLE (p = 0.016). Additionally patients with the Xx genotype had earlier onset of SLE than those with xx genotype (p = 0.025). The frequency of the combined ppXx genotype was significantly greater in childhood onset SLE than in controls (p = 0.0009) or adult onset SLE (p = 0.027).

PvuII and Xbal polymorphisms of ORα have already been investigated in other diseases, but this is the first time it has been studied in childhood onset SLE. The authors conclude that this indirectly supports the concept that oestrogen is involved in the pathogenesis of SLE. However the study was limited by the small number of cases of childhood onset SLE. Larger studies in different populations are now needed.


Please visit the Journal of Clinical Pathology website [www.jclinpath.com](http://www.jclinpath.com) for a link to the full text of this article.
Serological speciation of human schistosome infections by ELISA with a panel of three antigens

P Turner, K Laloo, J Bligh, M Armstrong, C J M Whitty, M J Doenhoff and P L Chiodini

*J Clin Pathol* 2004 57: 1193-1196
doi: 10.1136/jcp.2003.014779

Updated information and services can be found at:
http://jcp.bmj.com/content/57/11/1193

These include:

**References**
This article cites 11 articles, 8 of which you can access for free at:
http://jcp.bmj.com/content/57/11/1193#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/